ALK and non-small cell lung carcinoma: Crizotinib, for example, a tyrosine kinase inhibitor, was approved by the US Food and Drug Administration (FDA) in 2013 for the treatment of patients with non–small cell lung cancer (NSCLC) harbouring EML4-ALK rearrangements [9].